132 related articles for article (PubMed ID: 10223401)
1. D-3 receptor agonists: combined action neurologic and neuropsychiatric agents.
Cummings JL
J Neurol Sci; 1999 Feb; 163(1):2-3. PubMed ID: 10223401
[No Abstract] [Full Text] [Related]
2. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Bennett JP; Piercey MF
J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
[TBL] [Abstract][Full Text] [Related]
3. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
Piercey MF
Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole in refractory bipolar depression.
Goldberg JF; Frye MA; Dunn RT
Am J Psychiatry; 1999 May; 156(5):798. PubMed ID: 10327923
[No Abstract] [Full Text] [Related]
6. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.
Siuciak JA; Fujiwara RA
Psychopharmacology (Berl); 2004 Sep; 175(2):163-9. PubMed ID: 14985923
[TBL] [Abstract][Full Text] [Related]
7. DA agonists -- non-ergot derivatives: pramipexole: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S93-7. PubMed ID: 12211148
[No Abstract] [Full Text] [Related]
8. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.
Piercey MF; Hoffmann WE; Smith MW; Hyslop DK
Eur J Pharmacol; 1996 Sep; 312(1):35-44. PubMed ID: 8891576
[TBL] [Abstract][Full Text] [Related]
9. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Mierau J; Schneider FJ; Ensinger HA; Chio CL; Lajiness ME; Huff RM
Eur J Pharmacol; 1995 Jun; 290(1):29-36. PubMed ID: 7664822
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonists.
Factor SA
Med Clin North Am; 1999 Mar; 83(2):415-43, vi-vii. PubMed ID: 10093586
[TBL] [Abstract][Full Text] [Related]
11. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance.
Maggio R; Millan MJ
Curr Opin Pharmacol; 2010 Feb; 10(1):100-7. PubMed ID: 19896900
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole augmentation in panic with agoraphobia.
Marazziti D; Presta S; Pfanner C; Dell'Osso L; Cassano GB
Am J Psychiatry; 2001 Mar; 158(3):498-9. PubMed ID: 11230001
[No Abstract] [Full Text] [Related]
14. Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors.
Piercey MF; Hyslop DK; Hoffmann WE
Brain Res; 1997 Jul; 762(1-2):19-28. PubMed ID: 9262154
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
[TBL] [Abstract][Full Text] [Related]
16. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.
Black KJ; Hershey T; Koller JM; Videen TO; Mintun MA; Price JL; Perlmutter JS
Proc Natl Acad Sci U S A; 2002 Dec; 99(26):17113-8. PubMed ID: 12482941
[TBL] [Abstract][Full Text] [Related]
17. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
Presgraves SP; Borwege S; Millan MJ; Joyce JN
Exp Neurol; 2004 Nov; 190(1):157-70. PubMed ID: 15473989
[TBL] [Abstract][Full Text] [Related]
18. Introduction: pramipexole: a novel dopamine agonist for the treatment of Parkinson's disease.
de Yebenes JG
Eur J Neurol; 2000 May; 7 Suppl 1():1-2. PubMed ID: 11054151
[No Abstract] [Full Text] [Related]
19. Dopamine agonists in early therapy for Parkinson disease: promise and problems.
Tanner CM
JAMA; 2000 Oct; 284(15):1971-3. PubMed ID: 11035895
[No Abstract] [Full Text] [Related]
20. Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms.
Ramirez AD; Wong SK; Menniti FS
Eur J Pharmacol; 2003 Aug; 475(1-3):29-35. PubMed ID: 12954356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
